A 5-Day Regimen of Azacitidine for Lower-Risk Myelodysplastic Syndromes (RA or RARS): A Prospective Single-Arm Phase 2 Trial

Cancer Science - United States
doi 10.1111/cas.13739
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2017English

Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Biology of Blood and Marrow Transplantation
TransplantationHematology
2012English

Combination of Chidamide With Choep Regimen in Previously Untreated Patients With Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Cost-Effectiveness in Canada of Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndromes

Current Oncology
Oncology
2013English

Epigenetic Approaches in the Treatment of Myelodysplastic Syndromes: Clinical Utility of Azacitidine

OncoTargets and Therapy
OncologyPharmacology
2010English

Long-Term Outcome of Immunosuppressive Therapy for Japanese Patients With Lower-Risk Myelodysplastic Syndromes

International Journal of Hematology
Hematology
2013English

Colorectal Liver Metastatic Disease: Efficacy of Irreversible Electroporation—a Single-Arm Phase II Clinical Trial (COLDFIRE-2 Trial)

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy